Visceral Leishmaniasis Industry Insights: Market Forecast to 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Visceral Leishmaniasis Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The market for visceral leishmaniasis has experienced robust expansion over recent years. This market is projected to expand from $1 billion in 2024 to $1.06 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.7%. Historically, this expansion has been driven by factors such as an escalating disease burden, increased government funding, the introduction of amphotericin B, the development of miltefosine, expanding awareness initiatives, enhanced healthcare accessibility in affected regions, and the formation of public-private collaborations.

The visceral leishmaniasis market size is anticipated to experience substantial expansion over the next few years. It is projected to reach $1.32 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 5.7%. This expected growth during the forecast period stems from increased investment in vaccine development, strengthened global disease surveillance programs, growing public-private collaborations, improved funding for neglected tropical diseases, and the advancement of gene-based therapies. Prominent trends for the forecast period include CRISPR-based gene editing, artificial intelligence (AI)-driven drug discovery, nanotechnology-enhanced drug delivery, next-generation sequencing for parasite analysis, wearable biosensors for early detection, blockchain for medical supply chain management, smartphone-based diagnostic tools, and three-dimensional (3D) bioprinting for personalized treatment research.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23573&type=smp

What Are The Top Growth Drivers Impacting The Visceral Leishmaniasis Market Outlook?

The escalating prevalence of malnutrition is projected to boost the expansion of the visceral leishmaniasis market. Malnutrition itself is a physiological state stemming from inadequate or imbalanced nutrient intake crucial for optimal bodily functions. The uptick in malnutrition is attributed to food insecurity, which limits the availability of nutritious food, thereby leading to undernourishment and deficiencies in micronutrients that weaken the body’s immune defenses. Such impaired immune function renders the body more vulnerable to various infections, including visceral leishmaniasis. Insufficient nutrients compromise defense mechanisms, heightening the risk of severe disease and related complications. For example, in July 2024, figures from the Food and Agriculture Organization, an Italy-based specialized agency of the United Nations, showed that the number of undernourished people surged to 723.8 million in 2022, increasing from 708.7 million in 2021. Therefore, the ongoing rise in malnutrition is a key factor driving the growth of the visceral leishmaniasis market.

What Are The Different Segment Classifications Within The Visceral Leishmaniasis Market?

The visceral leishmaniasismarket covered in this report is segmented –

1) By Treatment: Antiparasitic; Antifungal; Other Treatments

2) By Diagnosis Method: Serological Tests; Molecular Tests; Microscopy; Culture Methods

3) By Route Of Administration: Oral; Injectable; Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy

5) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users

Subsegments:

1) By Antiparasitic: Pentavalent Antimonials; Miltefosine; Paromomycin; Sitamaquine; Combination Therapy

2) By Antifungal: Amphotericin B; Liposomal Amphotericin B (AmBisome); Azoles; Echinocandins; Polyenes

3) By Other Treatments: Immunotherapy; Monoclonal Antibodies; Vaccine-Based Approaches; Photodynamic Therapy; Gene Therapy

Which Key Trends Are Expected To Influence The Visceral Leishmaniasis Market In The Coming Years?

Firms active in the visceral leishmaniasis market are concentrating on creating improved treatment choices, including antiparasitic medications, to boost effectiveness and broaden patient access, especially in areas where the disease is prevalent. Antiparasitic drugs are medicinal compounds employed to combat parasitic infections, functioning by targeting the parasite’s biological processes and impeding its growth, replication, or persistence within the host organism. As an example, Zydus Lifesciences Limited, an Indian pharmaceutical firm, secured World Health Organization (WHO) prequalification in February 2024 for both the active pharmaceutical ingredient (API) and the formulation of miltefosine, intended for addressing leishmaniasis or kala-azar. Miltefosine operates as an oral antiparasitic medication by disturbing the cell membrane of the parasite and interfering with its metabolic activities, ultimately resulting in cellular demise. Furthermore, it suppresses the parasite’s growth and survival, thereby establishing itself as an effective oral therapeutic choice for visceral leishmaniasis or kala azar.

Which Global Market Leaders Are Shaping The Future Of The Visceral Leishmaniasis Sector?

Major companies operating in the visceral leishmaniasis market are Pfizer Inc., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Aurobindo Pharma Limited, Cipla Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Ltd, Xellia Pharmaceuticals, Knight Therapeutics Inc, Gufic Biosciences Ltd., United Biotech Private Limited, DNDi, TLC.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/visceral-leishmaniasis-global-market-report

How Does The Visceral Leishmaniasis Market Perform Across Key Geographic Regions?

North America was the largest region in the visceral leishmaniasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the visceral leishmaniasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Visceral Leishmaniasis Market Report:

https://www.thebusinessresearchcompany.com/customise?id=23573&type=smp

Browse Through More Reports Similar to the Global Visceral Leishmaniasis Market 2025, By The Business Research Company

Visceral Pain Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/visceral-pain-global-market-report

Liver Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report

Gene Delivery Technologies Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gene-delivery-technologies-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795